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Measurements Nominally at 2 Hours after Administration, Frank Saint-Marcoux, 1 Annick Rousseau, 1, 2 Yann Le Meur, 3 Marc Estenne, 4 Christiane Knoop, 4 Jean Debord, 1 and Pierre Marquet 1* (Departments of 1 Pharmacology and Toxicology and 3 Nephrology, University Hospital, 87042 Limoges cedex, France; 2 Laboratory of Biophysics, Faculty of Pharmacy, 87025 Limoges cedex, France; 4 Departments of Chest Medicine and Clinical Chemistry, Erasme University Hospital, 1070 Brussels, Belgium; * address correspondence to this author at: Service de Pharmacologie et Toxicologie, CHU Dupuytren, 87042 Limoges cedex, France; fax 33-555-05-61-62, e-mail marquet@ unilim.fr) Cyclosporine (CsA) blood concentrations measured 2 h after Neoral ® administration (c 2 ) are a sensitive predictor of clinical outcome in organ transplantation, as suggested by a recent prospective clinical trial in liver transplant patients (1 ). c 2 is now recommended as the target exposure index for the therapeutic drug monitoring (TDM) of CsA (2) (3) (4) (5) (6) (7) (8) . The aim of this study was to investigate, for different types of grafts, the concentration-time relationships around c 2 to evaluate the concentration error as a function of the sampling-time error and to identify the sampling-time range compatible with acceptable performance of this c 2 TDM strategy.
Data obtained from three different clinical trials were studied retrospectively. Each patient gave written informed consent, and each trial was approved by a local ethics committee (9 -11 ) . The three populations were as follows:
• Twenty stable adult renal transplant patients (grafted for more than 3 months and with stable renal function), from whom samples were collected immediately before a morning dose (t 0 ) and at 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, and 9 h post dose. These 20 full profiles were used for this study.
• Sixteen heart transplant patients for whom three full pharmacokinetic profiles (12 • Twenty stable adult lung transplant patients with (n ϭ 10) and without (n ϭ 10) cystic fibrosis. Three full pharmacokinetic profiles were collected within 1 week for each patient at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 h after a morning dose. A total of 29 profiles were obtained from cystic fibrosis transplant patients, and 30 from non-cystic fibrosis patients.
All the patients from these three clinical trials were dosed twice daily with microemulsified CsA (Neoral). The data are summarized in Table 1 .
For both kidney and lung transplant patients, CsA whole-blood concentrations were measured using an enzyme-multiplied immunoassay technique (Emit; DadeBehring Diagnostics). This method has an upper limit of quantification of 500 g/L. In the clinical trial conducted with cardiac transplant recipients, whole-blood CsA was measured with a fluorescence polarization immunoassay (FPIA; Abbott TDx). This method has an upper limit of quantification of 1500 g/L. For both assays, samples with CsA concentrations greater than the upper assay range were diluted 1:4 with human blank whole blood (100 L of sample ϩ 300 L of blank whole blood) and then reanalyzed.
Individual pharmacokinetic profiles were fitted using nonlinear regression (NLR) to a two-compartment pharmacokinetic model where the absorption phase is described by a ␥ distribution (12 ) . This pharmacokinetic model was specifically designed previously to deal with oral CsA profiles and was validated in the patient data sets analyzed here (9, 11, 13 ) . The consistency between observed and calculated concentrations within the first 4 h post dose was studied within each population. Seven or eight time points (i.e., 0.33, 0.66, 1, 1.5, 2, 3, and 4 h for all plus 2.5 h in heart transplant patients) were taken into account, representing a total of 140, 360, 203, and 210 concentrations for renal, heart, and lung cystic and noncystic transplant recipients, respectively. The relative differences between observed and predicted concentrations at all time points between 0 and 4 h post dose and the root mean squared error (14 ) were calculated using Excel (Microsoft). Regression and correlation analyses were performed using Statview (Abacus Concept).
For each patient and each profile, concentration values within Ϯ 15 min around 120 min post dose (i.e., at 105, 110, 115, 125, 130, and 135 min) were estimated by NLR using the same pharmacokinetic model. The relative concentration error (RCE) with respect to the concentration actually measured at 120 min (c 120 ) post dose was then computed as follows:
where c Calc is the calculated concentration at sampling times t ϭ 105, 110, 115, 125, 130, and 135 min post dose using NLR; and c 120 ("true") is the measured concentration at t ϭ 120 min. The mean RCE values were calculated for each virtual sampling time and each type of graft separately. A total of 124 full blood CsA concentration profiles over 12 h were analyzed for the present study. We found excellent correlation over the first 4 h after dosing between observed concentrations and concentration values calculated using NLR. Correlation coefficients (r 2 ) varied from 0.972 for cystic fibrosis transplant patients to 0.985 for renal recipients. Intercepts and slopes were not significantly different from 0 and 1, respectively. The good predictive performance resulted from the very small and nonsignificant differences between measured and calcu- lated concentrations [mean (SD) differences, 0.6 (4.5)% 0.7 (3.9)%, 0.2 (13)%, and 0.8 (9.6)% for renal, heart, lung cystic fibrosis, and lung non-cystic fibrosis transplant patients, respectively] and good precision (root mean squared error, 1.1-5.7%).
The calculated RCE values at each studied sampling time for each profile for the five different populations are shown in Fig. 1 . For each transplant patient, whatever the type of graft, the RCE value was within Ϯ 20% in a sampling-time interval from 110 to 130 min. A samplingtime error of Ϯ 15 min produced a RCE Ͼ20% (up to 30%) in a few heart and lung transplant patients. As can be inferred from Fig. 1 , in many patients t max was later than c 2 , which could be designated as "delayed absorption". The present data set included patients with a t max up to 5 h. In renal transplant patients, overestimation of c 2 was observed for t Ͻ120 min and underestimation for t Ͼ120 min. In lung and heart transplant patients, over-as well as underestimation of c 2 could be observed regardless of the time error, depending on the patient.
On the basis of data obtained in renal, heart, and lung transplant patients and using a validated pharmacokinetic method, the present study shows that when the sampling-time error around 2 h post dose increases, the relative concentration error and its interindividual variability also increase significantly. Although the impact of sampling-time error differed with the type of graft, an acceptable (Ϯ 20%) estimation of the true c 2 value was obtained within a time-error range of Ϯ 10min for all 124 profiles. Interestingly, for renal transplant patients, the mean RCE was always Ͻ10% within this time range.
The c 2 target values defined for CsA TDM in renal and de novo liver transplant patients have been proposed with a range of Ϯ 20% (e.g., 1.7 mg/L Ϯ 20% for the 0 -1 month post-transplantation period in renal transplantation) (4 ) . We compared this range with the interlaboratory CV values of the International Cyclosporin Proficiency Testing Scheme, taken as estimates of the analytical error (15 ) . For concentrations Ͻ500 g/L (n ϭ 12; results for the year 2002), the mean CVs were 10% for the Emit and 6.0% for the FPIA. The interlaboratory CV obtained with a whole blood sample to which 2000 g/L cyclosporin had been added was 7.9% for the Emit (n ϭ 38) and 7.2% for the FPIA (n ϭ 30).
In summary, numerous studies have promoted a Neoral monitoring strategy using CsA blood concentrations measured 2 h after drug administration, called c 2 , to improve the clinical benefits for transplant patients. Guidelines for c 2 interpretations propose target values with a range of Ϯ 20%. The present study shows that the accuracy of c 2 monitoring is highly dependent on the correct sampling time and that a substantial difference (up to 30%) from the 2-h values (which are themselves subject to analytical inaccuracy and imprecision) can occur with a sampling-time error of 15 min. Consequently, such time errors could lead to inappropriate dose adjustment and to inadequate immunosuppression or increased risk of adverse effects. Timing errors of Ϯ 10 min seem to be the acceptable limit for use of c 2 and subsequent dose adjustment of CsA.
